Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1023728

N#Cc1cccnc1N1CCC(CC(=O)O)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.58
RECQL P46063 1/20 0.58
LDHA P00338 1/20 0.54
MALT1 Q9UDY8 1/20 0.48
LCAT P04180 1/20 0.46
DRD2 P14416 1/20 0.46
HTR2A P28223 1/20 0.46
HSD11B1 P28845 2/20 0.46
HDAC2 Q92769 1/20 0.45
FFAR4 Q5NUL3 3/20 0.45
FFAR1 O14842 1/20 0.44
DRD4 P21917 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
RBP4 P02753 1/20 0.43
TTR P02766 1/20 0.43
ACKR3 P25106 1/20 0.42
PANK3 Q9H999 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13622633 0.93 KDM4E (0.66) KDM4ERECQLLDHAMALT1DRD2
SCHEMBL1023731 0.84 KDM4E (0.55) KDM4ERECQLLDHAMALT1LCAT
Trifluoroacetic Acid SCHEMBL1024810 0.83 FFAR4 (0.55) DRD2FFAR4FFAR1DRD4
Trifluoroacetic Acid SCHEMBL1022986 0.83 FFAR4 (0.48) KDM4EFFAR4FFAR1ALDH1A1
SCHEMBL1727887 0.79 KDM4E (0.60) KDM4ERECQLLDHAMALT1DRD2
SCHEMBL1727869 0.79 KDM4E (0.62) KDM4ERECQLLDHAMALT1DRD2
Trifluoroacetic Acid SCHEMBL1024081 0.79 KDM4E (0.54) KDM4EFFAR4ALDH1A1
SCHEMBL3110161 0.78 KDM4E (0.79) KDM4ERECQLLDHAMALT1DRD2
Trifluoroacetic Acid SCHEMBL1024329 0.77 ALDH1A1 (0.55) KDM4ERECQLDRD2FFAR4FFAR1
Acetic Acid SCHEMBL1026868 0.77 KDM4E (0.56) KDM4ERECQLLDHAMALT1LCAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK KDM4E 248/4885RECQL 3387/4885LDHA 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.